blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2582697

EP2582697 - NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  10.07.2020
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  25.08.2017
FormerGrant of patent is intended
Status updated on  10.04.2017
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip30.08.2024Lapse of the patent in a contracting state
New state(s): MT		published on 02.10.2024 [2024/40]
Applicant(s)For all designated states
Nanoform Cardiovascular Therapeutics Limited
100 Fetter Lane
London EC4A 1BN / GB
[2017/24]
Former [2013/17]For all designated states
Druggability Technologies IP Holdco (Jersey) Limited
12 Castle Street
St. Helier
Jersey JE2 3RT / GB
Inventor(s)01 / FILIPCSEI, Genovéva
Petneházy utca 66. I/103.
H-1135 Budapest / HU
02 / ÖTVÖS, Zsolt
Raisio utca 4, I/2.
H-6640 Csongrád / HU
03 / HELTOVICS, Gábor
Bíró utca 12.
H-1122 Budapest / HU
04 / DARVAS, Ferenc
Lisznyai utca 15.
H-1016 Budapest / HU
 [2017/39]
Former [2013/17]01 / FILIPCSEI, Genovéva
Petneházy utca 66. I/103.
H-1135 Budapest / HU
02 / ÖTVÖS, Zsolt
Raisio utca 4, I/2.
H-6640Csongrád / HU
03 / HELTOVICS, Gábor
Bíró utca 12.
H-1122 Budapest / HU
04 / DARVAS, Ferenc
Lisznyai utca 15.
H-1016 Budapest / HU
Representative(s)Molnar, Istvan
DANUBIA Patent and Law Office LLC
POB 198
1368 Budapest / HU
[2017/39]
Former [2013/17]Molnar, Istvan
DANUBIA Patent and Law Office LLC POB 198
1368 Budapest / HU
Application number, filing date11736150.117.06.2011
[2017/39]
WO2011HU00057
Priority number, dateHU2010P00032518.06.2010         Original published format: HU P1000325
[2013/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011158053
Date:22.12.2011
Language:EN
[2011/51]
Type: A1 Application with search report 
No.:EP2582697
Date:24.04.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 22.12.2011 takes the place of the publication of the European patent application.
[2013/17]
Type: B1 Patent specification 
No.:EP2582697
Date:27.09.2017
Language:EN
[2017/39]
Search report(s)International search report - published on:EP22.12.2011
ClassificationIPC:C07D413/06, A61P9/08, A61K31/5377
[2013/17]
CPC:
A61K9/14 (EP,US); A61K31/5377 (EP,US); A61P1/08 (EP);
A61P39/02 (EP); A61P9/08 (EP); C07D413/06 (EP,US);
Y10T428/2982 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/17]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NANOSTRUKTURIERTE APREPITANT-ZUSAMMENSETZUNGEN, HERSTELLUNGSVERFAHREN DAFÜR UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT[2013/17]
English:NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM[2013/17]
French:COMPOSITIONS NANOSTRUCTURÉES D'APRÉPITANT, LEUR PROCÉDÉ DE PRÉPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT[2013/17]
Entry into regional phase16.01.2013National basic fee paid 
16.01.2013Designation fee(s) paid 
16.01.2013Examination fee paid 
Examination procedure16.01.2013Examination requested  [2013/17]
14.08.2013Amendment by applicant (claims and/or description)
14.02.2014Despatch of a communication from the examining division (Time limit: M04)
24.06.2014Reply to a communication from the examining division
12.11.2014Despatch of a communication from the examining division (Time limit: M04)
10.03.2015Reply to a communication from the examining division
18.12.2015Despatch of a communication from the examining division (Time limit: M04)
14.04.2016Reply to a communication from the examining division
27.07.2016Despatch of a communication from the examining division (Time limit: M04)
24.11.2016Reply to a communication from the examining division
11.04.2017Communication of intention to grant the patent
21.08.2017Fee for grant paid
21.08.2017Fee for publishing/printing paid
21.08.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.02.2014
Opposition(s)Opponent(s)01  27.06.2018  02.07.2018  ADMISSIBLE
Alkermes Pharma Ireland Limited
Connaught House
1 Burlington Road
Dublin 4 / IE
Opponent's representative
Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 [2018/32]
11.07.2018Invitation to proprietor to file observations on the notice of opposition
13.09.2019Despatch of a communication from the opposition division (Time limit: M04)
20.03.2020Despatch of communication that the patent will be revoked
30.03.2020Legal effect of revocation of patent [2020/33]
Fees paidRenewal fee
03.05.2013Renewal fee patent year 03
19.05.2014Renewal fee patent year 04
01.12.2015Renewal fee patent year 05
30.06.2016Renewal fee patent year 06
20.06.2017Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.06.201505   M06   Fee paid on   01.12.2015
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL27.09.2017
AT27.09.2017
CY27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
MK27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
MT17.06.2019
ES18.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
DK30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
[2024/40]
Former [2022/34]AL27.09.2017
AT27.09.2017
CY27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
MK27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
ES18.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
DK30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/36]AL27.09.2017
AT27.09.2017
CY27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
MK27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
DK30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/33]AL27.09.2017
AT27.09.2017
CY27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
MK27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/31]AT27.09.2017
CY27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
MK27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/29]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
FR30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/26]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
PT27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/25]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
LU17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/24]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
HU18.06.2019
SE18.06.2019
BE30.06.2019
CH30.06.2019
LI30.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/23]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
GB17.06.2019
IE17.06.2019
IT17.06.2019
HU18.06.2019
SE18.06.2019
MC01.07.2019
NL01.07.2019
DE01.01.2020
Former [2020/21]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
IE17.06.2019
SE18.06.2019
MC01.07.2019
NL01.07.2019
Former [2020/20]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
SE18.06.2019
MC01.07.2019
NL01.07.2019
Former [2020/16]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
TR27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
SE18.06.2019
MC01.07.2019
Former [2020/10]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
SE18.06.2019
MC01.07.2019
Former [2020/08]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
MC01.07.2019
Former [2018/52]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SI27.09.2017
SK27.09.2017
SM27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/39]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
PL27.09.2017
RO27.09.2017
RS27.09.2017
SK27.09.2017
SM27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/24]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
RO27.09.2017
RS27.09.2017
SK27.09.2017
SM27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/23]AT27.09.2017
CZ27.09.2017
EE27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
RO27.09.2017
RS27.09.2017
SK27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
IS27.01.2018
Former [2018/21]CZ27.09.2017
FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
RS27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
Former [2018/12]FI27.09.2017
HR27.09.2017
LT27.09.2017
LV27.09.2017
RS27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
Former [2018/11]FI27.09.2017
HR27.09.2017
LT27.09.2017
RS27.09.2017
BG27.12.2017
NO27.12.2017
GR28.12.2017
Former [2018/08]FI27.09.2017
LT27.09.2017
NO27.12.2017
Former [2018/07]LT27.09.2017
NO27.12.2017
Cited inInternational search[X]WO03049718  (MERCK & CO INC [US], et al) [X] 1-8 * claim 3 *;
 [X]WO2007088483  (GLENMARK PAHRMACEUTICALS LTD [IN], et al) [X] 1-8 * Examples *;
 [X]WO2008104512  (SANDOZ AG [CH], et al) [X] 1-8 * Figures;; claim 1 *;
 [X]WO2009131930  (MERCK & CO INC [US], et al) [X] 1-8 * figure 2 *;
 [XP]WO2010092591  (USV LTD [IN], et al) [XP] 1-8 * claim 1 *;
 [XP]WO2010140132  (RANBAXY LAB LTD [IN], et al) [XP] 1-8* the whole document *;
 [X]  - SHONO Y ET AL, "Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 76, no. 1, ISSN 0939-6411, (20100601), pages 95 - 104, (20100601), XP027210087 [X] 1-8 * figure 8 *
 [X]  - WU Y ET AL, "The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (20041105), vol. 285, no. 1-2, doi:10.1016/J.IJPHARM.2004.08.001, ISSN 0378-5173, pages 135 - 146, XP004602823 [X] 1-8 * paragraph [2.3.1] *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2004.08.001
 [I]  - IAN OLVER ET AL, "Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD, AUCKLAND, NZ, (20070501), vol. 2, no. 1, doi:10.2147/IJN.S, ISSN 1176-9114, pages 13 - 18, XP009152304 [I] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.2147/IJN.S
by applicantUS5145684
 US5534270
 US5543133
 US5665331
 US5719147
 US5718388
 US5862999
 US6048859
 US6096742
 US6235735
 WO2007016582
 WO2007088483
 WO2007112457
 WO2007147160
 WO2008044102
 US2008214535
 WO2008104512
 WO2009001203
 WO2009108828
OppositionUS4826689
 US5145684
 US2007104792
 EP1455756
 WO2009133418
    - WU et al., "The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.", International Journal of Pharmaceutics, (20041105), vol. 285, pages 135 - 146, XP004602823

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2004.08.001
    - MERISKO-LIVERSIDGE ET AL et al., Advanced Drug Delivery Reviews, (20110109), vol. 63, pages 427 - 440, XP028374102

DOI:   http://dx.doi.org/10.1016/j.addr.2010.12.007
    - C TIMPE, "Combining Science and technology to create advanced drug delivery systems", APV fOCUS Group Drug Delivery, International Association for Pharmaceutical Technology Newsletter, (20100000), pages 1 - 16, XP055515006
    - ANGI ET AL et al., "Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties", European Journal of Pharmaceutics & Biopharmaceutics, (20140000), vol. 86, pages 361 - 368, XP028845346

DOI:   http://dx.doi.org/10.1016/j.ejpb.2013.10.004
    - MOSCHWITZER et al., "Chapter 5", MOSCHWITZER et al., THASSU D. ET AL., Nanoparticulate drug Delivery Systems, (20050629), pages 71 - 88, ISBN 0-8493-9073-7, XP055515020
    - ALI et al., "Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors.", International Journal of Pharmaceutics, (20090000), vol. 375, pages 107 - 113, XP026143342

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2009.03.029
    - M. AULTON, Pharmaceutics: the science of dosage form design, (19880000), pages 277 - 278, ISBN 0-443-03643-8, XP055515040
    - "Emend aprepitant capsul", FDA NDA 21-549, (20030300), pages 21 - 549, XP055515592
    - "Emend (fosaprepitant dimenglumine)", Emend (powder) FDA label NDA 22-023, (20080000), pages 1-17 - 2, 3, XP055515599
    - "SOLUPLUS 005346234", EUIPO, (20180524), pages 1 - 3, XP055515609
    - E. FALLON, Declaration
    - CHEN et al., "Quantitative Analysis of Powder Mixtures by Raman Spectrometry: the influence of particle size and its correction", Analytical Chemistry, (20120000), vol. 84, no. 9, pages 4088 - 4094, XP055515615
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.